PL433374A1 - Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego - Google Patents

Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego

Info

Publication number
PL433374A1
PL433374A1 PL433374A PL43337420A PL433374A1 PL 433374 A1 PL433374 A1 PL 433374A1 PL 433374 A PL433374 A PL 433374A PL 43337420 A PL43337420 A PL 43337420A PL 433374 A1 PL433374 A1 PL 433374A1
Authority
PL
Poland
Prior art keywords
determining
mesenchymal
gene panel
teratogenic potential
perinatal
Prior art date
Application number
PL433374A
Other languages
English (en)
Other versions
PL241520B1 (pl
Inventor
Tomasz OŁDAK
Tomasz KOLANOWSKI
Igor STEPANIEC
Original Assignee
Polski Bank Komórek Macierzystych Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polski Bank Komórek Macierzystych Spółka Akcyjna filed Critical Polski Bank Komórek Macierzystych Spółka Akcyjna
Priority to PL433374A priority Critical patent/PL241520B1/pl
Priority to EP21726182.5A priority patent/EP4127239A1/en
Priority to PCT/IB2021/052521 priority patent/WO2021191853A1/en
Publication of PL433374A1 publication Critical patent/PL433374A1/pl
Publication of PL241520B1 publication Critical patent/PL241520B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem wynalazku jest zestaw genów zawierający co najmniej jeden panel genów wybrany z: CDKN2A, CDH20, HAND2, PDGFR-a; lub ALOX15, CDH9, DRD4, ESM1, HEY1, NKX2-5; lub FUT3, PROM1, COL2A1, FOXA1, MYO3B; lub CLDN1, CPLX2, EOMES, FOXA2, HNF1B, HNF4A, LEFTY1, POU4F1; lub TDGF1, DNMT3B, IDO1, NANOG POUF5F1, SOX2; do zastosowania przy określaniu potencjału teratogennego populacji komórek mezenchymalnych (MSC) lub populacje komórek perinatalnych.
PL433374A 2020-03-27 2020-03-27 Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego PL241520B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL433374A PL241520B1 (pl) 2020-03-27 2020-03-27 Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego
EP21726182.5A EP4127239A1 (en) 2020-03-27 2021-03-26 The use of a gene panel to determine the teratogenic potential of mesenchymal and perinatal tissue-derived cells
PCT/IB2021/052521 WO2021191853A1 (en) 2020-03-27 2021-03-26 The use of a gene panel to determine the teratogenic potential of mesenchymal and perinatal tissue-derived cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL433374A PL241520B1 (pl) 2020-03-27 2020-03-27 Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego

Publications (2)

Publication Number Publication Date
PL433374A1 true PL433374A1 (pl) 2021-10-04
PL241520B1 PL241520B1 (pl) 2022-10-17

Family

ID=75954148

Family Applications (1)

Application Number Title Priority Date Filing Date
PL433374A PL241520B1 (pl) 2020-03-27 2020-03-27 Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego

Country Status (3)

Country Link
EP (1) EP4127239A1 (pl)
PL (1) PL241520B1 (pl)
WO (1) WO2021191853A1 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL443087A1 (pl) * 2022-12-08 2024-06-10 Polski Bank Komórek Macierzystych Spółka Akcyjna Sposób klasyfikacji komórek MSC ze względu na właściwości terapeutyczne

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4408979A1 (en) * 2021-09-30 2024-08-07 Polski Bank Komórek Macierzystych S.A. Expression analysis of a specific gene pool to determine whether the population of adipose tissue-derived mesenchymal cells (at-msc) selected for clinical application can undergo a transformation into neoplastic cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081174A2 (ja) * 2003-03-10 2004-09-23 Japan Science And Technology Agency 間葉系幹細胞検出用マーカー及び該マーカーを用いた間葉系幹細胞の識別方法
KR100888924B1 (ko) * 2007-06-04 2009-03-16 주식회사 제이비줄기세포연구소 인간 제대혈 유래 중간엽 줄기세포와 섬유아세포 분별방법
WO2015086052A1 (en) * 2013-12-10 2015-06-18 Swiss Stem Cell Foundation Culture media for in vitro differentiation of cardiomiocytes from adipose tissue-derived mesenchymal stem cells and method to select them
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL443087A1 (pl) * 2022-12-08 2024-06-10 Polski Bank Komórek Macierzystych Spółka Akcyjna Sposób klasyfikacji komórek MSC ze względu na właściwości terapeutyczne
PL247114B1 (pl) * 2022-12-08 2025-05-19 Polski Bank Komorek Macierzystych Spolka Akcyjna Sposób klasyfikacji komórek MSC ze względu na właściwości terapeutyczne

Also Published As

Publication number Publication date
WO2021191853A1 (en) 2021-09-30
EP4127239A1 (en) 2023-02-08
PL241520B1 (pl) 2022-10-17

Similar Documents

Publication Publication Date Title
PL433374A1 (pl) Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego
Wang et al. Longitudinal dynamics of the neutralizing antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
Olsen et al. Quantitative profiling of the activity of protein lysine methyltransferase SMYD2 using SILAC-based proteomics
Pervouchine et al. Integrative transcriptomic analysis suggests new autoregulatory splicing events coupled with nonsense-mediated mRNA decay
Fischbach et al. The C-terminal domain of p53 orchestrates the interplay between non-covalent and covalent poly (ADP-ribosyl) ation of p53 by PARP1
Nishi et al. Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity
Rochaix Chloroplast protein import machinery and quality control
Regan et al. Extracellular superoxide dismutase and oxidant damage in osteoarthritis
Sivachandran et al. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies
DK1280898T3 (da) Modificerede ES-celler og ES-cellespecifikt gen
GT200500233A (es) Produccion de a-beta
Kollmar et al. Nuclear codon reassignments in the genomics era and mechanisms behind their evolution
WO2021159020A3 (en) Compositions and methods for detection of coronavirus
DK1692276T3 (da) Fremgangsmåde til induktion af udvikling og terminal differentiering af hukommelses-B-celler
Taylor et al. Probing enzymatic activity–a radical approach
Kirino et al. Acquisition of the wobble modification in mitochondrial tRNALeu (CUN) bearing the G12300A mutation suppresses the MELAS molecular defect
Kalamvoki et al. Overexpression of the ubiquitin-specific protease 7 resulting from transfection or mutations in the ICP0 binding site accelerates rather than depresses herpes simplex virus 1 gene expression
Li et al. Approach to profile proteins that recognize post-translationally modified histone “tails”
MX2025001766A (es) Nucleasas guiadas por acido ribonucleico (arn) y fragmentos activos y variantes de las mismas y metodos de uso
Salinger et al. Technical comment on “Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis”
PY2022723A (es) Sistemas y métodos para detectar un organismo patógeno
Descotes et al. Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study
Ugarte et al. Proteome alteration in oxidative stress-sensitive methionine sulfoxide reductase-silenced HEK293 cells
Stubbe et al. Viral DNA binding protein SUMOylation promotes PML nuclear body localization next to viral replication centers. mBio 11: e00049-20
Yu et al. Single subunit degradation of WIZ, a lenalidomide-and pomalidomide-dependent substrate of E3 ubiquitin ligase CRL4CRBN